ZFP57 and breast carcinoma: In particular, ZNF148 appears to positively regulate the GABA transporter promoter (SLC6A1) who acts as an inhibitor of GnRH secretion [28]; ZNF574 and ZNF350 are associated with ovarian cancer and breast cancer, respectively [29, 30]; ZNF138 is located in the region involved in determining Williams syndrome that is sometimes associated with CPP [31]; ZNF664 is involved in metabolic syndrome [32, 33]; ZNF445 is related to Temple syndrome and acts as a regulator of imprinting along with ZFP57 [34–37]; ZNF365 plays a role in regulating genomic stability [38].